• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Pfizer to remain aggressive on obesity market after setback

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jan 08, 2024 at 10:32: PM
via Pfizer (PFE.N) will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

article source
 




Top Bottom
Back
Quote